PriceTargets.com logo

Guardant Health - GH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $80.86
  • Forecasted Upside: -25.49%
  • Number of Analysts: 24
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 23 Buy Ratings
  • 0 Strong Buy Ratings
$108.52 As of 12/4/2025 05:00 PM ET
▲ +2.56 (2.42%)

This chart shows the closing price for GH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardant Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GH

Analyst Price Target is $80.86
▼ -25.49% Downside Potential
This price target is based on 24 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $80.86, with a high forecast of $130.00 and a low forecast of $55.00. The average price target represents a -25.49% upside from the last price of $108.52.

This chart shows the closing price for GH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 24 contributing investment analysts is to moderate buy stock in Guardant Health. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 20 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 20 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 23 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 23 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 23 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$105.00 ➝ $130.00
10/30/2025CowenReiterated RatingBuy ➝ Buy
10/30/2025UBS GroupBoost TargetBuy ➝ Buy$80.00 ➝ $110.00
10/30/2025CitigroupBoost TargetBuy ➝ Buy$65.00 ➝ $100.00
10/30/2025MizuhoSet Target$100.00
10/30/2025Canaccord Genuity GroupSet Target$100.00
10/30/2025BarclaysBoost TargetOverweight ➝ Overweight$70.00 ➝ $85.00
10/30/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$75.00 ➝ $100.00
10/30/2025Evercore ISIBoost TargetOutperform ➝ Outperform$68.00 ➝ $90.00
10/30/2025BTIG ResearchBoost TargetBuy ➝ Buy$80.00 ➝ $100.00
10/22/2025Piper SandlerBoost TargetOverweight ➝ Overweight$60.00 ➝ $90.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025Evercore ISIBoost TargetOutperform ➝ Outperform$60.00 ➝ $68.00
10/2/2025BarclaysBoost TargetOverweight ➝ Overweight$60.00 ➝ $70.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$65.00 ➝ $75.00
9/25/2025CowenReiterated RatingBuy ➝ Buy
9/25/2025BTIG ResearchSet Target$80.00
9/25/2025Stifel NicolausSet Target$73.00
9/25/2025UBS GroupBoost TargetBuy ➝ Buy$70.00 ➝ $80.00
9/25/2025TD CowenBoost TargetBuy ➝ Buy$63.00 ➝ $72.00
9/25/2025Stifel NicolausBoost TargetBuy ➝ Buy$60.00 ➝ $70.00
9/25/2025MizuhoBoost TargetOutperform ➝ Outperform$65.00 ➝ $70.00
9/25/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$70.00 ➝ $75.00
9/25/2025William BlairReiterated RatingOutperform
9/25/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$60.00 ➝ $70.00
9/25/2025GuggenheimBoost TargetBuy ➝ Buy$56.00 ➝ $67.00
9/25/2025Wolfe ResearchUpgradePeer Perform ➝ Outperform$75.00
9/22/2025Wells Fargo & CompanyInitiated CoverageOverweight ➝ Overweight$72.00
9/22/2025Wells Fargo & CompanyInitiated CoverageOverweight ➝ Overweight$72.00
9/22/2025BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
9/4/2025BTIG ResearchBoost TargetBuy ➝ Buy$65.00 ➝ $70.00
7/31/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$57.00 ➝ $60.00
7/31/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$59.00 ➝ $61.00
7/14/2025Evercore ISIUpgradeStrong-Buy
6/13/2025MizuhoBoost TargetOutperform ➝ Outperform$60.00 ➝ $65.00
5/6/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00
5/5/2025ScotiabankReiterated RatingOutperform ➝ Outperform
5/5/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.00
5/1/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$60.00 ➝ $65.00
5/1/2025TD SecuritiesBoost TargetBuy ➝ Buy$56.00 ➝ $60.00
5/1/2025BarclaysBoost TargetOverweight ➝ Overweight$55.00 ➝ $60.00
5/1/2025Stifel NicolausBoost TargetBuy ➝ Buy$53.00 ➝ $60.00
5/1/2025UBS GroupBoost TargetBuy ➝ Buy$65.00 ➝ $70.00
4/10/2025BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $55.00
4/10/2025MizuhoInitiated CoverageOutperform$55.00
4/9/2025MizuhoUpgradeStrong-Buy
3/26/2025StephensReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00
3/6/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$42.00 ➝ $52.00
2/26/2025Piper SandlerBoost TargetOverweight ➝ Overweight$34.00 ➝ $50.00
2/24/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00
2/24/2025GuggenheimReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
2/24/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$42.00 ➝ $60.00
2/21/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$49.00 ➝ $56.00
2/21/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$39.00 ➝ $59.00
2/21/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$50.00 ➝ $55.00
2/21/2025Stifel NicolausBoost TargetBuy ➝ Buy$45.00 ➝ $53.00
1/28/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$36.00 ➝ $49.00
1/23/2025BarclaysInitiated CoverageOverweight$60.00
1/22/2025GuggenheimReiterated RatingBuy ➝ Buy
11/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$48.00 ➝ $50.00
11/7/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$32.00 ➝ $36.00
10/30/2024Sanford C. BernsteinLower TargetOutperform ➝ Outperform$40.00 ➝ $35.00
10/17/2024Leerink PartnersLower TargetOutperform ➝ Outperform$60.00 ➝ $50.00
8/21/2024UBS GroupBoost TargetBuy ➝ Buy$32.00 ➝ $40.00
8/13/2024Piper SandlerBoost TargetOverweight ➝ Overweight$30.00 ➝ $34.00
8/8/2024CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
8/8/2024TD CowenBoost TargetBuy ➝ Buy$41.00 ➝ $42.00
8/8/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$45.00 ➝ $48.00
8/8/2024Craig HallumBoost TargetBuy ➝ Buy$28.00 ➝ $37.00
7/30/2024BTIG ResearchBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
7/18/2024Bank of AmericaBoost TargetBuy ➝ Buy$28.00 ➝ $40.00
7/17/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$28.00 ➝ $32.00
6/28/2024GuggenheimUpgradeNeutral ➝ Buy$36.00
6/4/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$30.00 ➝ $38.00
6/3/2024Jefferies Financial GroupInitiated CoverageBuy$32.00
5/24/2024StephensReiterated RatingOverweight ➝ Overweight$44.00 ➝ $44.00
4/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$45.00 ➝ $30.00
4/24/2024Craig HallumInitiated CoverageBuy$28.00
4/15/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$32.00 ➝ $28.00
4/5/2024GuggenheimReiterated RatingNeutral
2/26/2024Piper SandlerLower TargetOverweight ➝ Overweight$40.00 ➝ $30.00
2/23/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$60.00 ➝ $45.00
2/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$50.00 ➝ $45.00
1/29/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$43.00 ➝ $37.00
12/14/2023GuggenheimInitiated CoverageNeutral
12/13/2023Wolfe ResearchInitiated CoveragePeer Perform
11/13/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform$27.00
11/8/2023Morgan StanleyLower TargetOverweight ➝ Overweight$55.00 ➝ $50.00
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$52.00 ➝ $45.00
10/2/2023CitigroupReiterated RatingBuy ➝ Buy$50.00
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$34.00
9/27/2023Piper SandlerUpgradeNeutral ➝ Overweight$40.00
9/8/2023William BlairReiterated RatingOutperform
8/8/2023Piper SandlerBoost TargetNeutral ➝ Neutral$30.00 ➝ $40.00
8/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$60.00 ➝ $55.00
8/4/2023CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $50.00
5/26/2023CitigroupUpgradeNeutral ➝ Buy$28.00 ➝ $40.00
5/15/2023Piper SandlerLower Target$35.00 ➝ $30.00
5/10/2023Credit Suisse GroupLower Target$60.00 ➝ $55.00
5/5/2023UBS GroupInitiated CoverageBuy$40.00
3/9/2023CitigroupDowngradeBuy ➝ Neutral$60.00 ➝ $33.00
3/3/2023Piper SandlerLower TargetNeutral$50.00 ➝ $35.00
2/27/2023Morgan StanleyLower TargetOverweight$73.00 ➝ $66.00
2/24/2023BTIG ResearchLower TargetBuy$60.00 ➝ $50.00
2/24/2023Credit Suisse GroupLower TargetOutperform$70.00 ➝ $60.00
2/24/2023Canaccord Genuity GroupLower TargetBuy$65.00 ➝ $60.00
2/24/2023CowenLower TargetOutperform$70.00 ➝ $53.00
2/24/2023JPMorgan Chase & Co.Lower TargetOverweight$75.00 ➝ $65.00
2/21/2023Morgan StanleyLower TargetOverweight$80.00 ➝ $73.00
2/16/2023StephensReiterated RatingOverweight$63.00
2/6/2023The Goldman Sachs GroupLower TargetBuy$70.00 ➝ $45.00
1/4/2023ScotiabankInitiated CoverageSector Outperform$36.00
12/16/2022Bank of AmericaBoost Target$65.00 ➝ $70.00
12/16/2022CowenLower Target$83.00 ➝ $70.00
12/16/2022BTIG ResearchLower Target$80.00 ➝ $60.00
12/16/2022CitigroupLower Target$80.00 ➝ $60.00
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$100.00 ➝ $85.00
11/7/2022StephensLower TargetOverweight$99.00 ➝ $90.00
11/4/2022The Goldman Sachs GroupLower TargetBuy$80.00 ➝ $70.00
11/4/2022CowenLower Target$110.00 ➝ $83.00
11/4/2022CowenLower Target$110.00 ➝ $83.00
11/4/2022Credit Suisse GroupLower TargetOutperform$80.00 ➝ $70.00
11/4/2022CitigroupLower Target$100.00 ➝ $80.00
11/1/2022Piper SandlerDowngradeOverweight ➝ Neutral$65.00 ➝ $50.00
10/19/2022Craig HallumInitiated CoverageBuy$88.00
10/5/2022StephensInitiated CoverageOverweight$99.00
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$80.00
8/8/2022The Goldman Sachs GroupLower TargetBuy$90.00 ➝ $80.00
8/8/2022Morgan StanleyLower TargetOverweight$85.00 ➝ $80.00
8/1/2022OTR GlobalDowngradePositive
6/2/2022Piper SandlerInitiated CoverageOverweight$65.00
5/6/2022CitigroupLower Target$120.00 ➝ $100.00
2/24/2022Stifel NicolausLower TargetBuy$160.00 ➝ $130.00
2/24/2022CowenLower TargetOutperform$170.00 ➝ $110.00
2/24/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$180.00 ➝ $165.00
2/24/2022Morgan StanleyLower TargetOverweight$125.00 ➝ $120.00
2/24/2022Wells Fargo & CompanyLower TargetOverweight$150.00 ➝ $115.00
2/24/2022CitigroupLower TargetBuy$180.00 ➝ $120.00
2/24/2022Leerink PartnersLower TargetOutperform$170.00 ➝ $140.00
2/15/2022Morgan StanleyLower TargetOverweight$150.00 ➝ $125.00
11/5/2021BTIG ResearchReiterated RatingBuy$159.00
11/5/2021Leerink PartnersLower TargetOutperform$180.00 ➝ $170.00
6/21/2021Wells Fargo & CompanyBoost TargetOverweight$145.00 ➝ $160.00
6/15/2021Raymond James FinancialInitiated CoverageMarket Perform
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00
5/27/2021William BlairReiterated RatingBuy
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00
5/23/2021Leerink PartnersReiterated RatingBuy
5/7/2021BTIG ResearchBoost TargetBuy$145.00 ➝ $160.00
5/7/2021Morgan StanleyLower TargetOverweight$175.00 ➝ $160.00
2/26/2021Morgan StanleyBoost TargetOverweight$130.00 ➝ $175.00
2/25/2021CitigroupBoost TargetBuy$155.00 ➝ $190.00
2/25/2021CowenBoost TargetOutperform$140.00 ➝ $190.00
1/20/2021Leerink PartnersBoost TargetOutperform$150.00 ➝ $190.00
1/11/2021Stifel NicolausInitiated CoverageBuy$175.00
12/17/2020BTIG ResearchBoost TargetBuy$132.00 ➝ $145.00
12/16/2020Smith Barney CitigroupBoost Target$145.00 ➝ $155.00
12/11/2020Leerink PartnersBoost TargetOutperform$130.00 ➝ $150.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 46 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 35 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
6/7/2025
  • 19 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 30 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 31 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 39 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 28 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
11/4/2025
  • 34 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 34 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $108.52
Low: $105.68
High: $109.59

50 Day Range

MA: $83.83
Low: $60.03
High: $111.25

52 Week Range

Now: $108.52
Low: $29.91
High: $112.43

Volume

1,905,484 shs

Average Volume

2,357,725 shs

Market Capitalization

$13.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?

The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Piper Sandler, Raymond James Financial, Inc., Scotiabank, Stephens, Stifel Nicolaus, TD Cowen, TD Securities, The Goldman Sachs Group, Inc., UBS Group AG, Weiss Ratings, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for GH.

What is the current price target for Guardant Health?

0 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Their average twelve-month price target is $80.86, suggesting a possible downside of 25.5%. Morgan Stanley has the highest price target set, predicting GH will reach $130.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $55.00 for Guardant Health in the next year.
View the latest price targets for GH.

What is the current consensus analyst rating for Guardant Health?

Guardant Health currently has 1 sell rating and 23 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GH.

What other companies compete with Guardant Health?

Other companies that are similar to Guardant Health include Veracyte, Natera, Fresenius Medical Care AG & Co. KGaA, Hims & Hers Health and BrightSpring Health Services. Learn More about companies similar to Guardant Health.

How do I contact Guardant Health's investor relations team?

Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company's listed phone number is (855) 698-8887 and its investor relations email address is [email protected]. The official website for Guardant Health is www.guardanthealth.com. Learn More about contacing Guardant Health investor relations.